This Medudy course is a conference report for physicians on the topic “ASCO 2026 – Updates on RCC & MIBC.”
Prof. Dr. med. Günter Niegisch, senior physician at the Department of Urology at the University Hospital of Düsseldorf, will summarize key study highlights from the conference for you.
This presentation will cover the results of a study on patients’ perception of toxicity following adjuvant ICI therapy and its impact on subsequent treatment evaluation in patients with renal cell carcinoma, as well as the primary results from the Phase II SAKK 06/19 trial, which investigated the combination of BCG with systemic chemo-immunotherapy in patients with muscle-invasive bladder cancer in a perioperative setting.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
This course was made possible with the generous support of Bayer and Johnson & Johnson.
By the end of this course, you will know:
- Some of the highlights of ASCO 2026
- The most important takeaways from the studies presented
- The expert's conclusion on the studies presented
